The Coronary CT Angiogram. What It Sees That a Stress Test Cannot.

The stress test has been the standard first-line investigation for suspected coronary artery disease for decades. It has a fundamental limitation that clinicians have understood for nearly as long: it detects only the minority of plaques that are obstructing enough blood flow to produce ischemia during exertion. The majority of plaques that cause acute myocardial infarction are non-obstructive at the time they rupture. A stress test does not see them.

The Mechanism

Understanding why this matters requires understanding how most heart attacks actually happen. There are two distinct modes of coronary artery disease progression.

The first mode is progressive luminal narrowing: a plaque grows slowly over years, eventually narrowing the artery’s diameter enough to reduce blood flow during exertion. This produces the classic pattern of stable angina, a predictable chest tightness with exertion that resolves with rest. This is the disease the stress test is designed to detect.

The second mode is plaque rupture. A non-obstructive plaque, one that may be narrowing the artery by only 30 to 40 percent of its diameter and producing no symptoms during exercise, develops a fissure in its fibrous cap. The lipid-rich necrotic core underneath is exposed to flowing blood. Platelet aggregation and thrombin generation begin immediately. Within minutes to hours, a thrombus can grow to completely occlude the vessel. This is the mechanism behind most acute MIs and sudden cardiac deaths.

The key word is non-obstructive. A lesion that reduces luminal diameter by 40 percent is not causing ischemia during a standard exercise stress test. It will produce a normal or negative stress test result. It can still rupture. Autopsy studies of fatal MI victims consistently show that the culprit lesion was non-obstructive in the majority of cases. The stress test, by design and by physics, cannot detect this category of disease.

The coronary CT angiogram (CCTA) uses a different physical approach. Iodinated contrast is injected into a peripheral vein. A high-resolution CT scanner, synchronized to the cardiac cycle using electrocardiographic gating, captures images during mid-diastole, the brief period when the heart is moving least and image sharpness is greatest. The resulting images show the coronary artery lumen and wall directly, with spatial resolution now approaching 0.4 millimeters on modern scanners.

From these images, trained readers can identify calcified plaque (dense, bright deposits in the vessel wall), non-calcified plaque (softer tissue density within the wall), mixed plaque (both components), the length and location of disease in each vessel, and the degree of luminal narrowing at each lesion, expressed as a percentage reduction in diameter. Clinically significant stenosis is conventionally defined as 50 percent or greater luminal narrowing, though functionally significant ischemia typically requires 70 percent or greater narrowing for most lesion geometries.

The fundamental difference from a stress test is this: the stress test is a functional test. It asks whether ischemia is occurring. The CCTA is an anatomical test. It asks whether plaque is present, in what quantity, and where. These are different questions, and for most patients with stable chest pain and intermediate pre-test probability, the anatomical question is more clinically useful than the functional one.

What the Evidence Shows

The SCOT-HEART trial, published in the New England Journal of Medicine by Newby and colleagues in 2018, is the primary evidence base for CCTA in stable chest pain evaluation. The trial enrolled 4,146 patients referred to cardiology clinics for evaluation of stable chest pain and randomized them to standard care or standard care plus coronary CTA.

At 5-year follow-up, the CCTA group had a significantly lower rate of fatal or nonfatal myocardial infarction: 2.3 percent versus 3.9 percent in the standard care group (hazard ratio 0.59, 95% CI 0.41 to 0.84, P = 0.004). This represents a 41 percent relative reduction in MI over 5 years, driven by better diagnosis and earlier appropriate treatment. (Newby et al., NEJM 2018) 5 / Solid

The mechanism behind the improved outcomes was clarification. Patients in the CCTA arm were more likely to have coronary artery disease correctly diagnosed: 491 patients (23.7 percent) had new CAD diagnoses after CCTA, compared to 166 (8.0 percent) in the standard care arm. Patients with confirmed disease were more likely to be started on preventive medications including statins, ACE inhibitors, and antiplatelet therapy. Patients without disease were more likely to have unnecessary investigations avoided. The scan improved the signal-to-noise ratio of the entire diagnostic and treatment pathway.

The PROMISE trial, published in NEJM by Douglas and colleagues in 2015, enrolled 10,003 symptomatic patients with no known coronary disease and randomized them to coronary CTA or functional stress testing at their site’s discretion (exercise ECG, nuclear imaging, or stress echocardiography). At a median follow-up of 25 months, there was no statistically significant difference in the primary composite outcome of death, MI, hospitalization for unstable angina, or major procedural complication (hazard ratio for CCTA versus functional testing 1.04, 95% CI 0.83 to 1.29). However, the CCTA arm resulted in higher rates of catheterization with a lower proportion of those catheterizations showing no obstructive disease, meaning the CCTA more accurately selected patients who needed invasive investigation and avoided catheterizations that returned normal results.

The DISCHARGE trial, published in NEJM in 2022 by Maurovich-Horvat and colleagues, enrolled 3,561 stable chest pain patients at intermediate pre-test probability who had been referred for invasive coronary angiography. They were randomized to CCTA-guided management or direct invasive angiography. The CCTA-guided group had equivalent outcomes at 3.5 years (5.8 percent versus 7.5 percent for the primary composite, P = 0.09 after adjustment), with substantially fewer major procedural complications (0.5 percent versus 1.9 percent). The trial established CCTA as a safe and clinically equivalent alternative to direct invasive angiography in stable patients at intermediate pre-test probability.

Taken together, these trials establish CCTA as the preferred initial anatomical investigation for stable chest pain with intermediate pre-test probability. It reduces MI compared to standard functional care (SCOT-HEART), is non-inferior to invasive angiography with fewer procedural complications (DISCHARGE), and better selects patients for needed invasive investigation (PROMISE).

The distinction between CAC scoring and CCTA deserves explicit clarification. The coronary artery calcium scan counts only calcified plaque deposits and produces a single aggregate Agatston unit score. It provides no information about the location of disease, its severity at any individual vessel, or the presence of non-calcified plaque. A CAC score of 200 tells you atherosclerosis is present; it does not tell you whether any of those lesions are causing stenosis, which vessels are affected, or whether the disease pattern is amenable to medical management or requires revascularization. The CCTA provides all of that information.

The two tests are complementary rather than competing. CAC scoring is an appropriate primary prevention screening tool for asymptomatic individuals at intermediate risk, where its cost, simplicity, and lack of contrast make it the efficient first step. CCTA is the appropriate tool when symptoms or clinical concern are high enough that direct anatomical visualization of the coronary arteries would change management, when a CAC result leaves the clinical question unanswered, or when the distinction between obstructive and non-obstructive disease determines the next step in care.

Fractional flow reserve derived from CT (FFRct) is a computational post-processing step applied to CCTA images. Using models of coronary hemodynamics derived from the scan’s geometric data, FFRct estimates whether a given stenosis is causing hemodynamically significant reduction in blood flow, defined by convention as an FFRct value below 0.80. The NXT trial, published in JACC in 2014 by Norgaard and colleagues, validated FFRct against invasive FFR in 251 patients with 484 lesions. Per-vessel diagnostic accuracy was 84 percent, sensitivity 86 percent, specificity 79 percent. The clinical value is that a single CCTA acquisition can now yield both anatomical data and a functional estimate, reducing the proportion of patients who need to proceed to invasive hemodynamic study.

The radiation dose of a modern CCTA ranges from approximately 1 to 5 millisieverts, depending on scanner generation, patient size, and the acquisition protocol used. Prospective ECG gating, which limits the X-ray exposure to a narrow window of the cardiac cycle, has substantially reduced dose from earlier retrospective gating protocols. For context, the average annual background radiation exposure in the United States is approximately 3 millisieverts from cosmic radiation and naturally occurring radioactive materials. A CCTA at 2 to 3 mSv is not a trivial exposure, but it is also not a reason to withhold a clinically indicated study. The exposure from a nuclear stress test is typically 8 to 16 mSv, depending on the radioisotope and protocol used.

High-Risk Plaque Features: What the Imaging Report Is Looking For

A CCTA report conveys more than stenosis severity. It characterizes plaque composition, and those compositional features carry independent prognostic significance that is not captured by percentage luminal narrowing alone. Understanding what these features mean is clinically relevant for any patient whose report includes them.

Low-attenuation plaque (LAP) refers to soft plaque material that appears at low Hounsfield unit values on CT imaging, typically below 30 HU relative to the surrounding blood pool. The low attenuation reflects a lipid-rich necrotic core — the same core material identified in vulnerable plaques on histological studies of culprit lesions after acute MI. The coronary artery calcium scan does not detect LAP at all; only CCTA images the soft plaque component.

Positive remodeling describes the outward expansion of the vessel wall to accommodate a growing plaque while initially preserving luminal diameter. This is the Glagov phenomenon, described by Seymour Glagov in a 1987 Circulation paper showing that coronary arteries expand outward before narrowing inward as plaque accumulates. A lesion with positive remodeling may show only 30 to 40 percent luminal narrowing while containing a large, potentially vulnerable plaque volume. Standard stenosis assessment underestimates its significance.

Spotty calcification — small, discrete calcium deposits within soft plaque — paradoxically confers higher rupture risk than the dense, confluent calcification that produces a high CAC score. Dense calcification indicates a stabilized, organized plaque. Spotty calcification within a soft core indicates a plaque that is still actively evolving.

Motoyama and colleagues, reporting in JACC in 2007, analyzed 1,059 consecutive patients who underwent CCTA and found that the combination of low-attenuation plaque and positive remodeling was associated with substantially higher rates of acute coronary syndrome over follow-up compared with plaques lacking these features. The presence of both features identified a specific subset of non-obstructive lesions — lesions that would be dismissed as “not significant” based on stenosis percentage alone — that were responsible for a disproportionate share of subsequent events.

This is the mechanistic reason why a CCTA showing non-obstructive disease is not automatically reassuring. The specific compositional characteristics of that non-obstructive disease determine its clinical trajectory. A cardiologist reading these features interprets a CCTA differently than one focused exclusively on stenosis percentage. Asking your cardiologist specifically about plaque characterization — not just whether any lesion exceeds 50 percent — is appropriate when reviewing results. 4 / Promising

What to Do This Week

1. If you have stable exertional chest discomfort that has not been evaluated, ask your physician specifically whether your pre-test probability warrants a CCTA as the first investigation rather than a functional stress test. The SCOT-HEART trial showed that starting with anatomy in stable chest pain reduced fatal and nonfatal MI by 41 percent over 5 years compared to standard care. That is a strong argument for prioritizing the anatomical question.

2. If you have had a negative stress test but remain symptomatic, ask whether a CCTA would add clinically meaningful information about non-obstructive plaque. These are different questions. A negative stress test says no lesion is currently obstructing enough blood flow to produce ischemia during exercise. A negative CCTA says no significant plaque is visible in the coronary circulation. Only one of those answers addresses the rupture-prone non-obstructive disease that causes most acute MIs.

3. If your CAC score falls between 100 and 400 and you want to know what that calcium represents anatomically, discuss CCTA with your cardiologist as the appropriate next step when that information would change management. A CAC of 200 tells you atherosclerosis is present; a CCTA tells you which vessels are involved, whether any lesion is causing luminal narrowing, and whether the pattern suggests medical management is sufficient or revascularization should be evaluated.

4. If your CCTA shows a stenosis of uncertain functional significance (typically 40 to 70 percent luminal narrowing), ask whether FFRct is available at your imaging center. This post-processing step can classify a borderline lesion as hemodynamically significant or not without requiring an additional invasive procedure.

5. Bring the CCTA report to a cardiologist rather than stopping at your primary care physician if the images show any non-calcified plaque, stenosis above 50 percent, or high-risk plaque features such as positive remodeling or low-attenuation plaque. These findings require clinical interpretation in the context of your symptoms and risk factors, not just documentation in the chart.

A normal CCTA is not the same as a normal stress test. It is a direct look at the coronary arteries with contrast enhancement at a resolution that can identify plaque accumulation years before any stenosis is present. That information changes what preventive therapy is appropriate, and in many cases it changes it substantially.